Professor

Shared appointment | 20% Pharmacy, 80% Chemistry and Molecular Biosciences
ARC Australian Professorial Fellow
Chair in Biological Chemistry
Professor of Pharmacy
Director of Pharmaceuticals TetraQ
Group Leader IMB Division of Structural Biology

Room: 1121 Building: 68 Chemistry Building
Phone: +61 7 336 69892
Email: i.toth@uq.edu.au


Introduction:

Professor Toth is a chemical engineer with a research focus on medicinal chemistry. He was awarded his PhD in 1972 and has since worked in Hungary, Canada and the United Kingdom before relocating to Australia in 1998. His major research interests are drug delivery, immunoadjuvants, synthetic vaccines and gene delivery. His research has attracted over $60 million in competitive grants, research contracts and investment funds in the past 10 years. He has over 300 peer-reviewed publications, 43 patents, and an excellent track record in research commercialization as a key founder of Alchemia (ASX listed), Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ (the commercial arm of Centre of Integrated Preclinical Drug Development).

Research and Collaborations:

Professor Toth works to develop synthetic peptide- and nanoparticle-based vaccines including the development of delivery platforms and safe synthetic adjuvants.
These vaccines target group A streptococcus, tropical diseases like malaria, hookworm and blood flukes, and the treatment of established tumors like those caused by human papilloma virus infection.

Professor Toth also works to improve the stability and delivery route of existing medicines or promising drug leads. Recent drugs of interest have been the natural pain peptides Enkephalin and Endomorphin-1, an orally available version of reproductive hormone Gonadotropin Hormone Releasing Hormone, and combination antibiotics that reduce bacterial resistance.

Professor Toth also investigates gene delivery with the aim of overcoming the hurdles of cell targeting and penetration, endosomal escape, and nuclear incorporation to develop effective gene therapies.

The Toth medicinal chemistry group has international collaborations with researchers at: The University of California, San Francisco (USA), Washington University in St Louis (USA), Emory University (Georgia, USA), Semmelweis University (Budapest, Hungary), University of Catania (Italy). In 2014 the Toth medchem group has 37 members in 2014 with 6 postdoctoral researchers, 18 PhD, 7 Masters and 3 Honours students.

Selected Publications:

Deng ZJ, Liang MT, Monteiro M, Toth I, Minchin RF. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 (CD11b/CD18) receptor activation and inflammation. Nature Nanotechnology. 2011;6(1):39-44. DOI: 10.1038/nnano.2010.250

Christie MP, Simerska P, Jen FE-C, Hussein WM, Rawi MFM, Hartley-Tassall LE, Day CJ, Jennings MP, Toth I. A drug delivery strategy: binding enkephalin to asialoglycoprotein receptor by enzymatic galactosylation. PLoS ONE. 2014;9(4):e95024. DOI: 10.1371/journal.pone.0095024

Moyle PM, Dai W, Zhang Y, Batzloff MR, Good MF, Toth I. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to Group A Streptococcal Vaccines. Bioconjugate Chemistry. 2014;25(5):965-978. DOI: 10.1021/bc500108b

Liu TY, Giddam AK, Hussein WM, Jia Z, McMillan NA, Monteiro MJ, Toth I, Skwarczynski M. Self-adjuvanting peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model. Current Drug Delivery 2014. Available online 01 Oct 2014. DOI: 10.2174/1567201811666141001155729


 

On this site